SL-701 is under clinical development by Stemline Therapeutics and currently in Phase I for Low-Grade Glioma. According to GlobalData, Phase I drugs for Low-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SL-701 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SL-701 overview
SL-701 is under development for the treatment of recurrent glioblastoma multiforme, pediatric high-grade glioma, diffuse intrinsic pontine gliomas, pediatric low-grade glioma, glioblastoma (GBM), anaplastic astrocytoma (AA) and gliosarcoma adult high-grade gliomas (relapsed/refractory) and low-grade gliomas. It is therapeutic cancer vaccine comprised of several short synthetic peptides that correspond to epitopes of targets including IL-13Ra2, EphA2, and survivin which is administered through subcutaneous route in the form of injection. SL-701 is developed based upon StemScreen platform.
It was under development for high-grade glioma and low-grade glioma.
Stemline Therapeutics overview
Stemline Therapeutics (Stemline), a subsidiary of A. Menarini Industrie Farmaceutiche Riunite Srl, is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells. The company pipeline products include TAGRAXOFUSP, ELACESTRANT, SL-701, MEN1611, MEN1611, MEN1309, FELEZONEXOR and SL-901. Stemline products treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), breast cancer, acute myeloid leukemia (AML), colorectal cancer (CRC) and solid tumors. It also carries out the development and commercialization of novel oncology therapeutics. The company has operations across Europe. Stemline is headquartered in New York, the US.
For a complete picture of SL-701’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
